193 related articles for article (PubMed ID: 26973396)
1. Factors associated with increased incidence of severe toxicities following yttrium-90 resin microspheres in the treatment of hepatic malignancies.
Roberson Ii JD; McDonald AM; Baden CJ; Lin CP; Jacob R; Burnett Iii OL
World J Gastroenterol; 2016 Mar; 22(10):3006-14. PubMed ID: 26973396
[TBL] [Abstract][Full Text] [Related]
2. Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center.
Piana PM; Gonsalves CF; Sato T; Anne PR; McCann JW; Bar Ad V; Eschelman DJ; Parker L; Doyle LA; Brown DB
J Vasc Interv Radiol; 2011 Oct; 22(10):1373-9. PubMed ID: 21764600
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.
Biederman DM; Titano JJ; Tabori NE; Pierobon ES; Alshebeeb K; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Nowakowski FS; Kim E
J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356
[TBL] [Abstract][Full Text] [Related]
4. Radioembolization with Yttrium-90 Microspheres for the Treatment of Liver Metastases of Pancreatic Adenocarcinoma: A Multicenter Analysis.
Kim AY; Frantz S; Brower J; Akhter N
J Vasc Interv Radiol; 2019 Mar; 30(3):298-304.e2. PubMed ID: 30819469
[TBL] [Abstract][Full Text] [Related]
5. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study.
Gangi A; Shah J; Hatfield N; Smith J; Sweeney J; Choi J; El-Haddad G; Biebel B; Parikh N; Arslan B; Hoffe SE; Frakes JM; Springett GM; Anaya DA; Malafa M; Chen DT; Chen Y; Kim RD; Shridhar R; Kis B
J Vasc Interv Radiol; 2018 Aug; 29(8):1101-1108. PubMed ID: 30042074
[TBL] [Abstract][Full Text] [Related]
6. Severe coagulopathy after 90Y microsphere administration: resemblance to the Kasabach-Merritt syndrome.
Hoffman MA; Rubin JI; Vinceguerra VP; Nowakowski FS; Warner RR
J Vasc Interv Radiol; 2008 Jul; 19(7):1099-102. PubMed ID: 18589326
[No Abstract] [Full Text] [Related]
7. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
[TBL] [Abstract][Full Text] [Related]
8. Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis.
Tsai AL; Burke CT; Kennedy AS; Moore DT; Mauro MA; Dixon RD; Stavas JM; Bernard SA; Khandani AH; O'Neil BH
J Vasc Interv Radiol; 2010 Sep; 21(9):1377-84. PubMed ID: 20691606
[TBL] [Abstract][Full Text] [Related]
9. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities.
Goin JE; Salem R; Carr BI; Dancey JE; Soulen MC; Geschwind JF; Goin K; Van Buskirk M; Thurston K
J Vasc Interv Radiol; 2005 Feb; 16(2 Pt 1):205-13. PubMed ID: 15713921
[TBL] [Abstract][Full Text] [Related]
10. Safety of repeated yttrium-90 radioembolization.
Lam MG; Louie JD; Iagaru AH; Goris ML; Sze DY
Cardiovasc Intervent Radiol; 2013 Oct; 36(5):1320-8. PubMed ID: 23354961
[TBL] [Abstract][Full Text] [Related]
11. Complications after 90Y microsphere radioembolization for unresectable hepatic tumors: An evaluation of 112 patients.
Peterson JL; Vallow LA; Johnson DW; Heckman MG; Diehl NN; Smith AA; Tzou KS; Paz-Fumagalli R; Kim S; Ko SJ; Daugherty LC; Kim GP; Brown N; Mori KW; Buskirk SJ
Brachytherapy; 2013; 12(6):573-9. PubMed ID: 23953810
[TBL] [Abstract][Full Text] [Related]
12. Hepatic yttrium-90 radioembolization for metastatic melanoma: a single-center experience.
Memon K; Kuzel TM; Vouche M; Atassi R; Lewandowski RJ; Salem R
Melanoma Res; 2014 Jun; 24(3):244-51. PubMed ID: 24638152
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
[TBL] [Abstract][Full Text] [Related]
14. Same-Day Yttrium-90 Radioembolization: Feasibility with Resin Microspheres.
Li MD; Chu KF; DePietro A; Wu V; Wehrenberg-Klee E; Zurkiya O; Liu RW; Ganguli S
J Vasc Interv Radiol; 2019 Mar; 30(3):314-319. PubMed ID: 30819470
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma and liver cirrhosis: assessment of the liver function after Yttrium-90 radioembolization with resin microspheres or after CT-guided high-dose-rate brachytherapy.
Rühl R; Seidensticker M; Peters N; Mohnike K; Bornschein J; Schütte K; Amthauer H; Malfertheiner P; Pech M; Ricke J
Dig Dis; 2009; 27(2):189-99. PubMed ID: 19546558
[TBL] [Abstract][Full Text] [Related]
16. Development of new hepaticoenteric collateral pathways after hepatic arterial skeletonization in preparation for yttrium-90 radioembolization.
Abdelmaksoud MH; Hwang GL; Louie JD; Kothary N; Hofmann LV; Kuo WT; Hovsepian DM; Sze DY
J Vasc Interv Radiol; 2010 Sep; 21(9):1385-95. PubMed ID: 20688531
[TBL] [Abstract][Full Text] [Related]
17. Resin-based Yttrium-90 microspheres for unresectable and failed first-line chemotherapy intrahepatic cholangiocarcinoma: preliminary results.
Jia Z; Paz-Fumagalli R; Frey G; Sella DM; McKinney JM; Wang W
J Cancer Res Clin Oncol; 2017 Mar; 143(3):481-489. PubMed ID: 27826686
[TBL] [Abstract][Full Text] [Related]
18. Predictors of Survival after Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases.
Weiner AA; Gui B; Newman NB; Nosher JL; Yousseff F; Lu SE; Foltz GM; Carpizo D; Lowenthal J; Zuckerman DA; Benson B; Olsen JR; Jabbour SK; Parikh PJ
J Vasc Interv Radiol; 2018 Aug; 29(8):1094-1100. PubMed ID: 29754852
[TBL] [Abstract][Full Text] [Related]
19. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction.
Garwood ER; Fidelman N; Hoch SE; Kerlan RK; Yao FY
Liver Transpl; 2013 Feb; 19(2):164-73. PubMed ID: 23008091
[TBL] [Abstract][Full Text] [Related]
20. Gastric injury from (90)Y to left hepatic lobe tumors adjacent to the stomach: fact or fiction?
Gates VL; Hickey R; Marshall K; Williams M; Salzig K; Lewandowski RJ; Salem R
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2038-44. PubMed ID: 26194715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
